FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising ...

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for ...